CAS: 6314-23-4; 2-(1-Pyrazolyl)Ethanol

相似化合物

16034-48-3 142890-12-8 10199-61-8

上下游产品

CAS号288-13-1 吡唑 | CAS号107-07-3 2-氯乙醇 | CAS号121751-71-1 2-(2-pyrazol-1-... | CAS号80200-14-2 4-(2-pyrazol-1-...

📜吡唑,2-氯乙醇置于sodium Ethanolate体系中,用 乙醇 作为反应溶剂,化学反应 0.5H,反应生成 2-(1H-吡唑-1-基)乙醇
参考文献:N-Terminal Strategy (N1-n4) Toward High Performance Liquid Crystal Materials
标题:N-Terminal Strategy (N1-n4) Toward High Performance Liquid Crystal Materials
摘要:Liquid Crystal Materials Have A Variety Of Applications In Many Fields Such As Display Techniques As Well As Photonics And Optics. However,Only Few Design Principles Have Been Disclosed On Liquid Crystal Materials With Different N-Heterocycles As The Terminal Groups,Which Hinder The Development Of The Heterocyclic Liquid Crystals. Here,A Strategy Of Molecular Design For N-Heterocyclic Liquid Crystal Materials Is Reported. On The Basis Of This Strategy,A Series Of Convenient N-Heterocycles Such As Pyrrole,Pyrazole,Imidazole,1,2,3-Triazole,1,2,4-Triazole,1,2,3,4-Tetrazole Were Applied To Synthesize The Novel Liquid Crystals. Most Of Them Have Proved To Exhibit Good Mesomorphic Behaviors Which Make Them Excellent Components In The Mixture Of The Lcds Materials. The Simple Attachment Of N-Heterocyclic Units To The Liquid Crystal Molecules Through A Mild Reaction Condition Will Provide A Good Prospect For The Design Of N-Heterocyclic Liquid Crystals. (C) 2015 Elsevier Ltd. All Rights Reserved.
DOI:10.1016/j.Tet.2015.11.013

专利信息

专利号:US-2007275968-A1
优先权日:2004-09-07
标 题 :Substituted Biphenyl Derivative
发明人：KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
权利人:KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
摘要:The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: n nwherein n R 1 represents a C 6 -C 10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C 1 -C 6 alkyl)amino group, a di-(C 1 -C 6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C 1 -C 6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R 2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R 3 represents a C 1 -C 6 alkyl group, and so on; and R 4 represents a C 1 -C 6 alkyl group, and so on.

专利号:US-9328138-B2
优先权日:2011-11-15
标题:HCV NS3 protease inhibitors
发明人：RUDD MICHAEL T; MCCAULEY JOHN; LIVERTON NIGEL; GRISÉ-BARD CHRISTIANE; BROCHU MARIE-CHRISTINE; CHARRON SYLVIE; AULAKH VIRENDER; BACHAND BENOIT; BEAULIEU PATRICK; ZAGHDANE HELMI; HAN YONGXIN; FERRARA MARCO; HARPER STEVEN; SUMMA VINCENZO; CHACKALAMANNIL SAMUEL; VENKATRAMAN SRIKANTH; SHAH UNMESH; VELAZQUEZ FRANCISCO
权利人:MERCK SHARP & DOHME; MSD ITALIA SRL; MERCK CANADA INC
摘要:The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.